Advances in the treatment of multiple myeloma: The role of thalidomide

被引：6

作者：

Ribas, C ^{[1
]}

Colleoni, GWB ^{[1
]}

机构：

[1] Univ Fed Sao Paulo, EPM, Dept Med, Discipline Hematol & Hemotherapy, Sao Paulo, Brazil

来源：

LEUKEMIA & LYMPHOMA | 2003年 / 44卷 / 02期

关键词：

multiple myeloma; thalidomide; treatment; review;

D O I：

10.1080/1042819021000035671

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Multiple myeloma (MM) accounts for 1% of all malignancies and 10% of malignant hematological neoplasms. In spite of high-dose therapy with stem cell rescue, relapse and disease resistance are common events in the course of the disease. Thalidomide (Thal) has been successfully used in such situations and it's use has also been expanded to the up-front therapy and as adjuvant to stem cell transplantation. Here, we review the underlying concepts and current clinical data regarding Thal in the treatment of MM.

引用

页码：291 / 298

页数：8

共 57 条

[1]

Alexanian R, 2001, BLOOD, V98, p163A

[2] Targeted therapy for multiple myeloma [J].

Anderson, KC .

SEMINARS IN HEMATOLOGY, 2001, 38 (03) :286-294

[3] Randomized trial experience of the Intergroupe Francophone du Myelome [J].

Attal, M ;

Harousseau, JL .

SEMINARS IN HEMATOLOGY, 2001, 38 (03) :226-230

[4] A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma [J].

Attal, M ;

Harousseau, JL ;

Stoppa, AM ;

Sotto, JJ ;

Fuzibet, JG ;

Rossi, JF ;

Casassus, P ;

Maisonneuve, H ;

Facon, T ;

Ifrah, N ;

Payen, C ;

Bataille, R .

NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (02) :91-97

[5] Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after nonmyeloablative conditioning [J].

Badros, A ;

Barlogie, B ;

Siegel, E ;

Cottler-Fox, M ;

Zangari, M ;

Fassas, A ;

Morris, C ;

Anaissie, E ;

Van Rhee, F ;

Tricot, G .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (05) :1295-1303

[6] EVIDENCE THAT THE CLONOGENIC CELL IN MULTIPLE-MYELOMA ORIGINATES FROM A PRE-SWITCHED BUT SOMATICALLY MUTATED B-CELL [J].

BAKKUS, MHC ;

VANRIET, I ;

VANCAMP, B ;

THIELEMANS, K .

BRITISH JOURNAL OF HAEMATOLOGY, 1994, 87 (01) :68-74

[7] High-dose therapy and innovative approaches to treatment of multiple myeloma [J].

Barlogie, B .

SEMINARS IN HEMATOLOGY, 2001, 38 (02) :21-27

[8]

Barlogie B, 2001, SEMIN ONCOL, V28, P577

[9] Thalidomide in the management of multiple myeloma [J].

Barlogie, B ;

Zangari, M ;

Spencer, T ;

Fassas, A ;

Anaissie, E ;

Badros, A ;

Cromer, J ;

Tricot, G .

SEMINARS IN HEMATOLOGY, 2001, 38 (03) :250-259

[10]

Barlogie B, 2000, BLOOD, V96, p514A

← 1 2 3 4 5 6 →